Antagonistes de l'angiotensine II et cancer: un bilan rassurant [Angiotensin II receptor blockers (ARBs) and cancer: a reassuring balance].

Détails

ID Serval
serval:BIB_AF1650250FDF
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Antagonistes de l'angiotensine II et cancer: un bilan rassurant [Angiotensin II receptor blockers (ARBs) and cancer: a reassuring balance].
Périodique
Revue Médicale Suisse
Auteur⸱e⸱s
Cassat M., Wuerzner G., Burnier M., Waeber B.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
2011
Volume
7
Numéro
308
Pages
1757-1760
Langue
français
Notes
Publication types: English Abstract ; Journal ArticlePublication Status: ppublish
Résumé
The effects of drugs on new cancer and cancer-related death are a major concern. Recently, a meta-analysis raised the possibility that ARBs might have an adverse impact in this respect. This point of view was highly debated until the publication of two other meta-analyses which did not demonstrate any increased risk of new cancer occurrence as well as of cancer related-death with the use of ARBs in patients with hypertension, heart failure and/or nephropathy. This illustrates that the results of meta-analyses should be interpreted cautiously and critically in order to avoid biased conclusions. Overall the bulk of evidence today indicates that ARBs are not associated with an increased cancer risk.
Mots-clé
Angiotensin Receptor Antagonists/administration & dosage, Angiotensin Receptor Antagonists/adverse effects, Humans, Hypertension/drug therapy, Meta-Analysis as Topic, Neoplasms/chemically induced, Risk Assessment, Risk Factors, Treatment Outcome
Pubmed
Création de la notice
20/03/2012 16:27
Dernière modification de la notice
20/08/2019 16:18
Données d'usage